Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation

Meggane Melchior, Pierre-Eric Juif, Géraldine Gazzo, Nathalie Petit-Demoulière, Virginie Chavant, Adrien Lacaud, Yannick Goumon, Alexandre Charlet, Vincent Lelièvre, Pierrick Poisbeau

► To cite this version:

Meggane Melchior, Pierre-Eric Juif, Géraldine Gazzo, Nathalie Petit-Demoulière, Virginie Chavant, et al.. Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation. Pain, 2018, 159 (12), pp.2630-2640. 10.1097/j.pain.0000000000001375 . hal-02166011

HAL Id: hal-02166011

<https://hal.science/hal-02166011>

Submitted on 4 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

PAIN

Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation --Manuscript Draft--

Manuscript Number:	PAIN-D-17-01200R1
Full Title:	Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation
Article Type:	Research Paper
Keywords:	early life stress, spinal nociceptive processing, hyperalgesia, oxytocin, allopregnanolone, HDAC inhibitor, epigenetic
Corresponding Author:	Pierrick Poisbeau, PhD CNRS and University of Strasbourg Strasbourg, FRANCE
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	CNRS and University of Strasbourg
Corresponding Author's Secondary Institution:	
First Author:	Meggane Melchior, MSc
First Author Secondary Information:	
Order of Authors:	Meggane Melchior, MSc Pierre-Eric Juif, PhD Géraldine Gazzo, MSc Nathalie Petit-Demouliere, MSc Virgine Chavant, MSc Adrien Lacaud, Tech Yannick Goumon, PhD Alexandre Charlet, PhD Vincent Lelièvre, PhD Pierrick Poisbeau, PhD
Additional Information:	
Question	Response
Have you posted this manuscript on a preprint server (e.g., arXiv.org, BioXriv, PeerJ Preprints)?	No

ABSTRACT

Oxytocin (OT), known for its neurohormonal effects around birth, has recently been suggested for being a critical determinant in neurodevelopmental disorders. This hypothalamic neuropeptide exerts a potent analgesic effect through an action on the nociceptive system. This endogenous control of pain has an important adaptive value but might be altered by early life stress (ELS), possibly contributing to its long-term consequences on pain responses and associated comorbidities. We tested this hypothesis using a rat model of neonatal maternal separation (MS) known to induce long term consequences on several brain functions including chronic stress, anxiety, altered social behavior and visceral hypersensitivity. We found that adult rats with a history of MS were hypersensitive to noxious mechanical/thermal hot stimuli and to inflammatory pain. We failed to observe OT receptor-mediated stress-induced analgesia as well as OT anti-hyperalgesia after carrageenan inflammation. These alterations were partially rescued if MS pups were treated by intraperitoneal daily injection during MS with OT or its downstream second messenger allopregnanolone. The involvement of epigenetic changes in these alterations was confirmed since neonatal treatment with the HDAC inhibitor SAHA, not only normalized nociceptive sensitivities, but also restored OT receptor-mediated stress-induced analgesia as well as the endogenous anti-hyperalgesia in inflamed MS rats. There is growing evidence in the literature that ELS might impair the nociceptive system ontogeny and function. This study suggests that these alterations might be restored while stimulating OT receptor signaling or HDAC inhibitors, using molecules that are currently available or part of clinical trials for other pathologies.

Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation

Melchior M¹, Juif PE¹, Gazzo G¹, Petit-Demoulière N¹, Chavant V¹, Lacaud A¹, Goumon Y¹, Lelièvre V¹, Charlet A^{1,2} & Poisbeau P¹

¹ Centre National de la Recherche Scientifique and University of Strasbourg, Institut des Neurosciences Cellulaires et Intégratives, F-67084 Strasbourg, France.

² University of Strasbourg Institute for Advanced Study, Strasbourg, France

Corresponding author:

Prof. Pierrick Poisbeau, CNRS UPR-3212, Institut des Neurosciences Cellulaires et Intégratives (INCI), Research group « Molecular Determinants of Pain », 5 rue Blaise Pascal, 67084 Strasbourg, France.

Tel: (+33) 3 68 85 14 76 - Fax: (+33) 3 88 61 33 47 - Email: poisbeau@inci-cnrs.unistra.fr

Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation

Melchior M¹, Juif PE¹, Gazzo G¹, Petit-Demoulière N¹, Chavant V^{1,2}, Lacaud A¹, Goumon Y^{1,2}, Charlet A^{1,3}, Lelièvre V¹, & Poisbeau P¹

¹ Centre National de la Recherche Scientifique and University of Strasbourg, Institut des Neurosciences Cellulaires et Intégratives, F-67084 Strasbourg, France.

² Mass spectrometry facilities of the CNRS UPR3212, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la recherche Scientifique, Strasbourg, France.

³ University of Strasbourg Institute for Advanced Study, Strasbourg, France

Corresponding author:

Prof. Pierrick Poisbeau, CNRS UPR-3212, Institut des Neurosciences Cellulaires et Intégratives (INCI), Research group « Molecular Determinants of Pain », 5 rue Blaise Pascal, 67000 Strasbourg, France.

Tel: (+33) 3 68 85 14 76 - Fax: (+33) 3 88 61 33 47 - Email: poisbeau@inci-cnrs.unistra.fr

RESUME

Oxytocin (OT), known for its neurohormonal effects around birth, has recently been suggested for being a critical determinant in neurodevelopmental disorders. This hypothalamic neuropeptide exerts a potent analgesic effect through an action on the nociceptive system. This endogenous control of pain has an important adaptive value but might be altered by early life stress (ELS), possibly contributing to its long-term consequences on pain responses and associated comorbidities. We tested this hypothesis using a rat model of neonatal maternal separation (NMS) known to induce long term consequences on several brain functions including chronic stress, anxiety, altered social behavior and visceral hypersensitivity. We found that adult rats with a history of NMS were hypersensitive to noxious mechanical/thermal hot stimuli and to inflammatory pain. We failed to observe OT receptor-mediated stress-induced analgesia as well as OT anti-hyperalgesia after carrageenan inflammation. These alterations were partially rescued if NMS pups were treated by intraperitoneal daily injection during NMS with OT or its downstream second messenger allopregnanolone. Involvement of epigenetic changes in these alterations was confirmed since neonatal treatment with the **histone deacetylase (HDAC)** inhibitor SAHA, not only normalized nociceptive sensitivities, but also restored OT receptor-mediated stress-induced analgesia as well as the endogenous anti-hyperalgesia in inflamed NMS rats. There is growing evidence in the literature that ELS might impair the nociceptive system ontogeny and function. This study suggests that these alterations might be restored while stimulating OT receptor signaling or HDAC inhibitors, using molecules that are currently available or part of clinical trials for other pathologies.

INTRODUCTION

Oxytocin (OT) is a nonapeptide synthesized by hypothalamic neurons mainly located in the paraventricular (PVN) and supraoptic (SON) nuclei [1]. OT acts both as a neurohormone when released into the blood via the posterior pituitary or as a neurotransmitter when synaptically released into the spinal cord (SC) and supraspinal regions. Recently, our laboratory identified a small population of 30 parvocellular neurons in the PVN which coordinate the peripheral and spinal release of OT to limit inflammatory pain symptoms [2]. Indeed parvocellular OT neurons of the PVN trigger OT secretion in superficial and autonomic layers of the SC where OT receptors are found [1]. OT displays anti-nociceptive properties by increasing GABAergic inhibition in the SC thus decreasing excitability in superficial and deep SC neurons [1]. In addition to these central-related effects, a peripheral component of OT-mediated analgesia via a direct effect at the dorsal root ganglion (DRG) level has been documented [3].

Activation of the OT analgesic system occurs under different conditions such as inflammatory sensitization [2], neuropathic pain [4], or forced swim stress (FSS) [5]. In the carrageenan model of inflammatory sensitization, spinal OT levels are increased for at least 24 h and OT receptor-mediated local production of the neurosteroid allopregnanolone (AP) leads to a sustained GABAergic activity to maintain spinal antinociceptive control [6]. After a non-noxious FSS, OT is also responsible for significant and transient stress-induced analgesia (SIA) [5]. In this context, a deficit in OT signaling might be related to neurodevelopmental brain pathologies such as autism spectrum disorders [7; 8].

The development of the nociceptive system starts before birth and follows a similar pattern in the rat and in the human fetus [9; 10]. It is well accepted that the developmental stage of the rat just after birth is similar to that of the human fetus at the beginning of the 3rd trimester of gestation.

1 Descending controls of pain mature during the first 3 weeks after birth in the rat [11] and begin to
2 mature during the end of the 3rd semester in humans [12]. At the SC level, spinal inputs and
3 chloride homeostasis undergo re-organization steps after birth to be fully matured [13; 14] making
4 them possibly vulnerable to early adverse events. Neonatal maternal separation (NMS) is a well-
5 established model of early life stress (ELS) that induces long term neuroendocrine and behavioral
6 changes in rodents, with impact on the HPA axis, social and cognitive behaviors, and sensory and
7 nociceptive systems [15; 16]. Long-term consequences of NMS are indeed visceral hypersensitivity
8 [17], epigenetic changes, and associated sensory dysfunctions [18; 19]. Recently, a chronic adult
9 treatment with histone deacetylase (HDAC) inhibitor was shown to be efficient to counteract
10 NMS-induced visceral hypersensitivity [19].
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 In this study, we used behavioral measures and *in vivo* electrophysiological recordings from SC
27 dorsal horn neurons to characterize the long-term consequences of NMS on the oxytocinergic
28 descending control of pain. Then, we aimed to prevent the development of NMS pain phenotype
29 using pharmacological tools, targeting the OT system or epigenetic factors early during the
30 postnatal period.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

MATERIALS AND METHODS

Animal care and neonatal maternal deprivation procedure

Female Wistar rats with litters were housed in a temperature-controlled room (22°C) under a 12h light-dark cycle (lights on at 07:00 AM), with *ad libitum* access to food and water. All experiments were conducted in conformity with the recommendations of the European Committee Council Direction of September 22, 2010 (2010/63/EU), with an authorization for animal experimentation from the French Department of Agriculture (License 67-116 to PP) and with a procedure agreement evaluated by the regional ethical committee (CREMEAS authorization number APAFIS#7678-20 16112223027528 v2).

At birth, litters were randomly assigned to two groups: Neonatal NMS and non-separated control litters. The litters allocated to the NMS group were removed from the nest cages 3 h per day from postnatal days 2 (P2) to 12 (P12) and placed on a heating pad (37°C) in a separate cage. The litters allocated to the control group remained with their mother in their home cages during the entire NMS interval and received no special handling other than that necessary to change the bedding of their cage. Pups were weaned at P21 and housed four rats per cage before being randomly chosen at 8 weeks or more for behavioral analysis or electrophysiological recordings. In each experiment, animals were chosen randomly in at least two different litters. Both males and females were used in this study, as no sex specific differences could be seen for the different neurophysiological and behavioral measures.

Measure of basal mechanical and thermal nociception

Mechanical nociception was measured on adult rats with a calibrated forceps (Bioseb, Vitrolles, France) as previously described [20]. Briefly, the habituated rat was loosely restrained with a towel

masking the eyes in order to limit stress by environmental stimulations. The tips of the forceps were placed at each side of the paw and a gradually increasing force was applied. The pressure producing withdrawal of the paw corresponded to the nociceptive threshold value. Thermal nociception was measured by a blind experimenter with the Hargreaves method, as previously described [21]. Briefly, rats were placed in plexiglas boxes (20cm x 25cm x 45cm) for a 15-20 minutes habituation period and then hindpaws were exposed to a radiant heat and the latency time required to induce paw withdrawal was recorded and considered as the nociceptive heat threshold. For both tests, measurements were performed three times for each hindpaw and values were averaged.

Forced swim stress

At adulthood, rats were exposed to a forced swim stress procedure (FSS) in a Plexiglas® cylinder (diameter: 30 cm; wall height: 60 cm), filled with water (height: 40 cm) at a temperature of 20°C for 10 minutes. After FSS exposure, animals were gently dried. Mechanical thresholds were measured before (baseline) and 15 min after FSS in both NMS and control animals. This protocol has been described to be associated with a plasmatic and spinal release of oxytocin [5]. The oxytocinergic contribution of FSS to SIA was confirmed in a subset of rats receiving an intrathecal (i.t) injection of 10µL of OTR antagonist dOVT ((d(CH₂)₅¹,Tyr(Me)²,Thr⁴,Orn⁸,des-Gly-NH₂⁹)-Vasotocin, Bachem, Germany) at 200µM or 10µL saline 30 minutes before FSS.

Carrageenan Inflammatory pain model

To induce a painful inflammatory sensitization in the rat, 150µL of carrageenan (3% in NaCl 0.9%, Sigma Aldrich, Germany) were injected in the plantar surface of the right hindpaw for behavioral

experiments, whereas injections in both hindpaws were performed for electrophysiological. Control animals received either similar injections of NaCl 0.9% or no injection.

In vivo recording of spinal cord neurons and analysis

Male and female rats were anaesthetized with isoflurane (2 %; pushed by pressurized air at a flow rate of 0.5 L.min⁻¹) and body temperature was regulated using a thermostatically controlled heating blanket (Harvard Apparatus Ltd, France) maintaining the body temperature at 37°C. Animals were set up in a stereotaxic frame (La Précision Cinématographique, Eaubonne, France), with the cervical and sacral vertebrae firmly held. The lumbar SC (L4-L5) was exposed by laminectomy. After removal of the meninges, the SC surface was covered with a thin isolating layer of mineral oil. This opening allowed us to record SC neurons and apply several drugs directly on the SC. At the end of the experiment, animals were killed with an overdose of isoflurane.

Single unit extracellular in vivo recordings were made from wide dynamic range (WDR) neurons, located in lamina V and receiving peripheral sensory messages mediated by A β , A δ and C-type primary afferent fibers. In the lumbar enlargement of the SC, we monitored voltage changes through stainless microelectrodes (FHC, Bowdoin, USA) connected to an extracellular differential amplifier (DAM-80, WPI, Aston, UK). Electrical signals were then digitized (Power 1401 CED, Cambridge, UK), processed with the Spike 2 software (CED Cambridge, UK). Neurons were characterized by their responses to transcutaneous electrical stimulation of the hindpaw receptive field as previously described [22]. Electrical stimulation was applied through two thin cutaneous pin electrodes placed in the center of the receptive field on the hindpaw. Increasing intensities were applied from 1 V to C fiber activation threshold (duration of 1 ms). Trials consisted of a train of 90 electrical stimuli (3 x C-type fiber threshold) applied repetitively (1 Hz) to the excitatory

receptive field. This method has been usually used to obtain a stable and reproducible “wind up” [23], a property of C-type nociceptive fibers. The electrically-evoked response of the neuron was captured and displayed as a post-stimulus histogram, for A-type and C-type discharge. Action potentials appearing early after the stimulus artifact were classified as A-type (0-50 ms) whereas the delayed response corresponded to C-type (50-800 ms).

Spinal cord sampling and PCR analysis

Lumbar spinal cord samples were collected, reconstituted in a guanidine thiocyanate/ β -mercaptoethanol preparation using ultraturax and stored at -80°C. Total RNA was extracted according to a protocol derived from the original procedure of Chomczynski and Sacchi [24], consisting of two independent total RNA extractions separated by a DNaseI treatment ((TURBO DNase™, Ambion, Life technologies, Saint Aubin, France), as previously described in detail [25]. 800ng RNA were used for reverse transcription with the RT iScript kit (Bio-Rad, Marnes-la-Coquette, France). Quantitative PCR was performed using SYBR Green Supermix (Bio-Rad), on the iQ5 Real Time PCR System (Bio-Rad). Amplifications were carried out in 42 cycles (20s at 95°C, 20s at 60°C and 20s at 72°C). Standardization was made possible using standard curves made from serial dilutions of samples, and amplification data is shown as relative gene expression, calculated as the ratio between cDNA concentration of the gene of interest and that of the housekeeping gene. Preliminary experiments showed that among the different classic housekeeping genes routinely analyzed in the laboratory, and compared with 18S ribosomal RNA, hypoxanthin-guanine phosphoribosyltransferase (HPRT) transcripts remained highly stable among the different samples. Therefore, HPRT was selected as the housekeeping gene to analyze and evaluate potential changes in gene expression in all experiments presented here. To specifically amplify mRNA encoding various rat proteins, we designed specific primer sets (sense and antisense

1 respectively) using Oligo6.0 and M-fold softwares. Primer sequences for all genes of interest can
2 be found in supplementary table 1. Samples were accurately dispensed in duplicates using a
3 robotic workstation (Freedom EVO100, Tecan, Lyon, France), and amplification efficacy given by
4 standard curves was always close to 100% ($\pm 2\%$), whilst amplification specificity was assessed by a
5 melting curve study.
6
7
8
9
10
11
12
13
14

15 Neonatal rescue procedure

16
17 To reverse NMS long term consequences on pain behavior, a pharmacological neonatal treatment
18 was performed in NMS pups. During NMS protocol, all pups in the litter were injected with the
19 same molecule and then tested at adulthood to investigate the long-term efficiency of neonatal
20 treatment. OT (Bachem, Weil am Rhein, Germany), the HDAC inhibitor SAHA (Suberoylanilide
21 hydroxamic acid, Vorinostat, ApexBio Technology, Houston, USA), or vehicle (NaCl, oil or 10%
22 DMSO respectively) were injected intraperitoneally (i.p. 10 μ L) at 1mg/kg and 5mg/kg respectively
23 once daily (o.d) during the NMS procedure (*i.e* from P2 to P12). In another subset of animals,
24 allopregnanolone (AP, Santa Cruz biotechnology, Dallas, USA) was injected subcutaneously at
25 10mg/kg once every two days during the NMS procedure. To avoid unnecessary supplementary
26 handling of the pups, injections were performed at the beginning of the separation process. Pups
27 were then normally weaned at P21, and no special handling was performed until P45, when the
28 efficiency of neonatal treatment was assessed for each neonatal group using behavioral testing.
29 First, mechanical thresholds were measured prior (baseline) and after FSS (SIA measurement).
30 Then one week later, the efficacy of the OT descending control of pain after carrageenan
31 inflammation of the hindpaw was measured with the same protocol as the one previously
32 described (using spinal dOVT injection 24H after inflammation).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Drugs and Treatments

OT receptor (OTR) agonists and antagonist, as well as V1aR antagonist were prepared as a concentrated solution in water (1mM) and diluted to the needed concentration in NaCl (0.9%) before experiment. The selective OTR antagonist dOVT (d(CH₂)⁵-Tyr(Me)-[Orn⁸]-vasotocine) was used at a final concentration of 1 µM in Saline (NaCl 0.9%). dOVT was injected i.t. (volume 20 µL) or directly on the spinal cord in electrophysiological recordings (volume 500 µL). V1aR antagonist [Phenylacetyl¹,O-Me-D-Tyr²,Arg^{6,8},Lys⁹]-vasopressinamide (AV1AR: Sigma Aldrich, Saint-Louis, France) was injected i.t. at a concentration of 1µM (volume 20µL). OT and TGOT ((Thr⁴,Gly⁷)-Oxytocin) (Bachem, Weil am Rhein, Germany) were used as an agonists for OTRs. OT was dissolved in saline and injected i.t or i.p. at a concentration of 10 µM or 1mg/kg, respectively. TGOT was also dissolved in NaCl 0.9% and injected at a concentration of 1 µM (i.t.). Allopregnanolone and SAHA were freshly prepared before the experiment. Allopregnanolone was used at 10mg/kg and dissolved in mineral oil by sonication at 4°C. The non-selective HDAC inhibitor SAHA was dissolved in 10% DMSO and injected i.p. at a concentration of 5mg/kg.

Statistical analysis

All data are expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using GraphPad Prism 6 software (LaJolla, CA, USA). For each experiment, parametric analysis was used only after verifying the normal distribution of the values. Unpaired Student t-test was used to compare baseline nociceptive sensitivity and OTR and oxytocinase (OTase) expression in NMS and CTRL rats. Repeated measures Two-Way ANOVA followed by Sidak post hoc test was used to analyze inflammatory symptoms and to analyze wind-up efficiency. Repeated measures Two-Way ANOVA followed by Tukey's post hoc test was used to evaluate the effect of

OT and TGOT spinal application in control and NMS rats. One way ANOVA and Tukey post-hoc tests were used to compare the effects of spinal application of dOVT in control or NMS rats, to evaluate the efficiency of SIA in both groups, to analyze the success of the rescue experiments on baseline nociceptive sensitivities and to evaluate spinal mRNA expression of 3 α -hydroxysteroid dehydrogenase (3 α -HSD), 5 α -reductase type II (5 α -red II), P450scc and translocator protein (TSPO). Mann-Whitney test was used to compare the effects of spinal application of the V1aR antagonist in control and NMS rats. Kruskal Wallis (KW) followed by Dunn's post hoc test was used to compare wind-up frequencies and spinal expression of histone deacetylases (HDAC) transcripts. Differences were considered to be statistically significant for $p < 0.05$.

RESULTS

Consequences of NMS on the nociceptive sensitivity and on the efficacy of oxytocinergic SIA

We first characterized the long-term effects of NMS on baseline mechanical and thermal nociceptive thresholds (Figure 1A), as well as the intensity of stress-induced mechanical analgesia (SIA) measured after FSS (Figure 1B). Compared to the control group, NMS animals exhibited hypersensitivity to both mechanical and thermal stimulation at adulthood ($P > 100$). NMS rats displayed significantly lower mean pressure thresholds (control: 445.5 ± 6.1 g, $N = 12$; NMS: 268.5 ± 7.1 g, $N = 12$; $p < 0.001$, unpaired Student t-test, $t = 18.83$, $df = 22$) and paw withdrawal latencies to noxious heat (control: 21.1 ± 0.8 s, $N = 12$; NMS: 12.6 ± 0.4 s, $N = 12$; $p < 0.001$, unpaired Student t-test, $t = 9$, $df = 22$).

Figure 1 near here

Previous studies showed that both central and peripheral release of OT contributed to SIA after a FSS [26; 22]. Because NMS is known to alter the normal reactivity to stress and lead to a dysfunction of the HPA axis, we investigated the efficacy of the oxytocinergic component of SIA in NMS animals (Figure 1B). As expected, the FSS paradigm induced a significant analgesia 20 minutes after swim in the control group (Figure 1B). Mean baseline-corrected mechanical thresholds were increased by 239 ± 12.3 g in the control group ($N=8$) but only by 10.7 ± 23.4 g in the NMS group ($N=8$). An injection of dOVT prior to FSS decreased SIA intensity to 56.9 ± 20.1 g in the control group ($N=8$) and had no effect in the NMS group ($N=8$) where it varied of 20.75 ± 20.7 g ($p < 0.001$, One-Way ANOVA, $F = 28.9$). These results suggest a blunted adaptation to stressful conditions in NMS rats associated with possible dysfunction of the oxytocinergic descending control of pain.

Behavioral response to a painful inflammatory sensitization by carrageenan

We next compared the intensity and time course of inflammatory pain symptoms triggered by an intraplantar hindpaw injection of carrageenan to possibly highlight differences in the expression of mechanical/thermal hyperalgesia in control and NMS rats (Figure 2). In both groups, carrageenan injection induced a sustained mechanical and thermal hyperalgesia which peaked 7 h after injection, as previously described [6]. Although basal mechanical nociceptive thresholds (i.e., before carrageenan injection) were significantly lower in NMS rats, the time course of mechanical hyperalgesia was not significantly different between both groups (Figure 2A1-B1). In the control group, mean pressure threshold dropped from 445.8 ± 18.7 g to 30.1 ± 5.1 g, 7 h after injection ($N = 6$; repeated measures two-way ANOVA, treatment x time, $F_{(12,120)} = 63.81$, $p < 0.001$) and mechanical hyperalgesia lasted for at least 6 days for control. As mentioned above, at baseline, NMS rats exhibited a lower mean pressure threshold of 295.5 ± 4.8 g ($N = 6$), which further decreased to 70.8 ± 12.6 g, 7 h after carrageenan injection. As illustrated in Figure 2B1, hyperalgesia was detected at a significant level for 6 days ($N = 6$; repeated measures two-way ANOVA, treatment x time, $F_{(12,120)} = 30.78$, $p < 0.001$). Concerning thermal hot sensitivity, 7 h after carrageenan injection mean latencies decreased to 3.3 ± 0.6 s and 4.2 ± 0.8 s in control and NMS rats ($N=6$ per group) respectively. Interestingly, thermal hot hyperalgesia persisted for at least 1 days for control rats and up to 4 days in NMS rats (Figure 2B2) (repeated measures two-way ANOVA, treatment x time, $F_{(8,80)} = 13.67$, $p < 0.001$ for CTRL and $F_{(10,100)} = 10.69$, $p < 0.001$ for NMS).

Figure 2 near here

Oxytocinergic contribution to the intensity of carrageenan-induced pain symptoms and to the spinal cord processing of nociceptive messages

In the carrageenan model of inflammatory sensitization, spinal concentrations of OT are elevated during the early phase of inflammation and have been shown to limit pain sensitivity [22]. To investigate whether NMS affects OTRergic anti-hyperalgesia, i.t application of the selective OTR antagonist dOVT was performed 24 hours after carrageenan injection. As OT may act via the activation of vasopressin V1a receptors (V1ARs) at high concentrations, we also examined a possible contribution of these receptors using i.t application of V1aR selective antagonist.

In the control group and as previously shown [6], a single i.t injection of dOVT (1 μ M, 20 μ L), induced a rebound of mechanical and thermal hyperalgesia. Anti-hyperalgesia mediated by OTR could be seen in the CTRL group as a decrease in the mean baseline-corrected mechanical threshold 4 h (*i.e.* 28h after carrageenan) after dOVT injection by -75.6 ± 8.4 g (N= 10 Figure 3A). This decrease was absent in the saline-treated group (-2 ± 8.4 g, N=10) (One-way ANOVA $F = 17.5$, $p < 0.001$). For thermal withdrawal latency (Figure 3B), OTR anti-hyperalgesia could also be seen as a significant decrease in the mean values after dOVT compared to saline (N = 10; One-way ANOVA, $F = 9.3$, $p < 0.001$). This corresponded to a change of -3.9 ± 0.6 s (N=10) and of 1.1 ± 0.8 s (N=10), for the dOVT and saline groups, respectively. Intrathecal injection of the V1aR antagonist was without effect on mechanical (before: 155.25 ± 3.2 g; after i.t. injection: 177.25 ± 18.2 g, N = 4; Mann-Whitney test: $U = 4.0$; $p = 0.3429$) or thermal nociceptive threshold (before: 10.0 ± 0.9 s; after i.t. injection: 11.0 ± 0.9 s, N=4; Mann-Whitney test: $U = 5.0$; $p = 0.4571$) in the control group of rats.

Both results confirmed OTR activation to be responsible for a limitation of pain symptoms early after carrageenan injection in control animals. Interestingly, there were no changes in the mean

mechanical (dOVT: delta of 5.8 ± 10.8 g, N=8; saline: delta of -27.2 ± 9 g, N=7; One-way ANOVA $F=17.5$ $p<0.001$) and thermal hyperalgesia values (dOVT: delta of -1 ± 0.7 s, N=8; saline: delta of 0.1 ± 0.7 s, N=7; One-way ANOVA $F=9.3$ $p<0.001$) in NMS animals. As for control rats, a single i.t. injection of the V1aR antagonist did not change mechanical (before: 164.65 ± 9.9 g; after i.t. injection: 145.75 ± 10.3 g, N = 8, Mann-Whitney test: $U = 20.0$; $p = 0.2241$) nor thermal nociceptive thresholds (before: 6.13 ± 0.4 s; after i.t. injection: 5.5 ± 0.5 s, N=8; Mann-Whitney test: $U = 22.0$; $p = 0.3514$) in NMS rat.

Together, this suggests that NMS has long-term consequences on the efficacy of OTR-mediated spinal analgesia, at least in short-term inflammatory painful sensitization.

Figure 3 near here

To further characterize this NMS-altered OTR-mediated analgesia in NMS adult rats, we recorded WDR neurons in the SC of anesthetized rats and analyzed the spinal processing of nociceptive messages through the expression of windup, a nociceptive-specific short-term plasticity [27]. As illustrated in figure 4, windup recorded 24 h after carrageenan injection was significantly amplified after the spinal application of dOVT ($1\mu\text{M}$). In control animals (N=6, figure 4A), windup protocol led to an average maximum frequency of 23.6 ± 1.5 spikes/s. This value significantly increased to a maximum frequency of 44.1 ± 4.8 spikes/s after dOVT application (N = 6; two-way repeated measures ANOVA, treatment x time, $F_{(14,70)} = 7.811$; $p < 0.0001$). As shown in figure 4B, we did not see any change in windup frequencies in NMS animals (N=6) after dOVT application (before application: 26.8 ± 4.3 spikes/s; after application: 25 ± 4.1 spikes/s; two-way repeated measures ANOVA, treatment x time, $F_{(14,70)} = 1.366$; $p = 0.1936$). Summary of results can be found in figure 4C (Kruskal-Wallis test: $KW = 8.9$; $p = 0.03$).

Figure 4 near here

Altogether, electrophysiological and behavioral experiments suggested that the OT descending inhibitory control of pain is inefficient in NMS rats.

OTR expression and OTR-induced analgesia

In order to better understand the possible molecular and cellular alterations induced by NMS, we first analyzed the expression of OTR and a possible dysfunction of its downstream signaling, focusing on the SC as it is the first relay for nociceptive messages. There were no difference in the spinal expression of OTR gene transcripts between control (N=7; 3.1 ± 0.9 spinal relative expression) and NMS (N=8; 2.4 ± 0.2 spinal relative expression) rats (unpaired Student's t-test, $p = 0.44$, $t = 0.78$, $df = 13$), as illustrated in figure 5A.

Figure 5 near here

To further confirm that OTR were not only expressed at similar levels in both groups but were equally functional, we measured the analgesic behavioral response to i.t injection of OT (1 μ M 20 μ L) or to the selective agonist TGOT (1 μ M 20 μ L) in CTRL and NMS rats (Figure 5B). In CTRL animals OT (N = 8) or TGOT (N = 8) significantly increased mechanical thresholds 20 minutes after the injection (OT: from 467.4 ± 19.4 g to 741.6 ± 67.1 g; TGOT: from 471.8 ± 14.6 g to 813.2 ± 26.3 g; Two-way repeated measures ANOVA, treatment x time, $F_{(4,40)} = 14.67$; $p < 0.0001$). Both OT (N = 7) or TGOT (N = 8) significantly increased mechanical thresholds 20 minutes after the injection in a reversible manner in NMS animals (OT: from 288.4 ± 5.0 g to 533.9 ± 13.1 g; TGOT: from 246.7 ± 11.2 g to 460.1 ± 17.3 g; Two-way repeated measures ANOVA, treatment x time, $F_{(11,38)} = 66.94$; $p < 0.001$). This result confirmed that spinal OTR are functional in NMS rats and capable of producing efficient analgesia. We thus checked whether NMS could lead to an increase in the spinal degradation of OT. As illustrated in Supplementary Figure 1A, we found

no difference in the spinal expression of oxytocinase (OTase) mRNA between control and NMS rats (N=8; unpaired Student t-test, $t = 0.1317$, $df = 14$; $p = 0.8971$).

Neonatal treatments with OT and allopregnanolone

Many studies provided evidence that OT in the neonatal period could be protective against early life adverse events or lesions [28; 29]. Moreover, NMS is known to reduce maternal behavior towards the pups and a subsequent altered development of OT systems, possibly leading to blunted OT levels [30]. This includes molecular mechanisms affecting chloride homeostasis and the production of neuroprotective neurosteroids such as allopregnanolone [6].

In a first set of experiments, we treated NMS rat pups o.d. from P2 to P12 with OT (1mg/kg in 0.9% NaCl, i.p., Figure 6). As shown in figure 6A, neonatal OT treatment fully restored normal mechanical nociceptive thresholds when measured at P50 (control: 320.7 ± 10.9 g, $N = 12$; NMS: 235.1 ± 6.9 g, $N = 8$; OT-treated NMS: 320.4 ± 6.3 g, $N = 10$; One-way ANOVA, $F = 23.39$, $p < 0.001$). OT neonatal treatment also restored an efficient analgesia after FSS (Figure 6B; delta for Control group: 261.8 ± 18.6 g, $N = 9$; NMS: 17.8 ± 11.6 g, $N = 8$; OT-treated NMS: 168.9 ± 10.4 g, $N = 9$; One-way ANOVA, $F = 30.08$, $p < 0.001$). In contrast to SIA after FSS, neonatal OT treatment failed to restore OT anti-hyperalgesia 24 hours after carrageenan-induced inflammation, measured as before using i.t dOVT injection (Figure 6C). The dOVT injection did not significantly amplified mechanical hyperalgesia (delta for NMS: 5.8 ± 10.9 g, $N = 8$; OT-pretreated NMS: 45.6 ± 19.7 g, $N = 8$; One-Way ANOVA, $F = 14.28$, $p < 0.001$).

Figure 6 near here

Recently, an original long-lasting molecular mode of action of OT in SC neurons has been proposed. It leads to the stimulation of AP synthesis, a neurosteroid well-known for its analgesic

and neuroprotective roles [31]. We thus tried to restore OT function in NMS rats by submitting newborn pups to AP during the NMS period. As illustrated in the different panels of figure 6, a neonatal treatment with s.c AP (10mg/kg) between P2 and P12 was associated with a mean mechanical threshold at adulthood which was higher (i.e., hyposensitivity) than those measured in control animals (Figure 6A; Control: 320.7 ± 10.9 g, N = 12; AP-treated NMS: 394.1 ± 21.9 g, N = 10; One way ANOVA, $F = 23.39$, $p < 0.001$). As for neonatal OT treatment, SIA could be restored by AP treatment (Figure 6B; baseline corrected mean mechanical threshold in AP-treated NMS: 351 ± 47 g, N = 8, One Way ANOVA, $F = 30.08$, $p < 0.001$). As previously reported, endogenous OT anti-hyperalgesia could not be revealed after dOVT i.t. injection (Figure 6C; AP-treated NMS: -23 ± 16 g, N = 8; One Way ANOVA, $F = 14.28$, $p < 0.001$). Taken together, our results likely suggested NMS to be associated with a deficit in OT signaling. However, we found no significant difference in the spinal transcripts levels of 3α -hydroxysteroid dehydrogenase (3α -HSD), 5α -reductase type II (5α -red II), nor cholesterol side-chain cleavage enzyme (P450scc), enzymes involved in AP synthesis (Supplementary Figure 1B; N = 8; One way ANOVA, $F = 0.7409$, $p = 0.6384$). Similarly, spinal translocator protein (TSPO) mRNA levels remained unchanged in NMS rats compared to controls.

NMS-induced epigenetic alterations and rescue of MS pain phenotype by targeting histone deacetylases

The long-term consequences of NMS on pain sensitivity and on the rat ability to cope with stress/pain potentially rely on epigenetic mechanisms. Indeed, several reports highlight the effects of NMS on the HPA axis and on maternal behavior [32; 33]. We thus measured the spinal expression of a set of transcripts coding for several epigenetic factors at different time points

(from P7 to P100) in NMS and control animals (Figure 7A). We found that mRNA levels for some class I (HDAC 1 and 8) and class II HDAC (HDAC 7) were significantly increased in NMS animals at P24 (HDAC 1 and 7), P45 (HDAC 1, 7 and 8) and until P100 for HDAC 7 (Kruskal-Wallis; HDAC1 : KW = 60.33 , p < 0.0001 , N = 7 ; HDAC 7 : KW = 61.41 , p < 0.0001 , N = 7 ; HDAC 8 : KW = 49.28 , p < 0.0001 , N = 6).

In particular, HDAC 7 mRNA spinal expression was significantly increased in NMS animals compared to controls at P24 (0.49 ± 0.04 relative expression in CTRL and 1.22 ± 0.11 in NMS), as illustrated in figure 7B, and levels remained significantly higher until adulthood at P100 (0.36 ± 0.03 relative expression in CTRL and 1.01 ± 0.04 in NMS). These results likely suggest that NMS triggers long lasting changes in gene expression, involving at least HDAC functions.

Figure 7 near here

We hence performed a neonatal chronic treatment from P2 to P12 with SAHA (10 mg/kg i.p.), a non-selective HDAC I and II inhibitor. Neonatal treatment of newborn pups with SAHA during NMS was associated with mean mechanical nociceptive thresholds at adulthood (P50) which were similar to the control group (Figure 7C; Control: 320.7 ± 10.9 g, N = 8; SAHA-treated NMS: 303.8 ± 9.4 g, N = 10; One way ANOVA, F = 14.28, p < 0.001). This treatment also partially restored SIA after FSS (Figure 7D; SAHA-treated: 130 ± 26.7 g, n = 7; One Way ANOVA, F = 34.73, p < 0.001). Interestingly, SAHA treatment partially restored OT anti-hyperalgesia after carrageenan inflammation (Figure 7E; Control: 75.6 ± 8.4 g; SAHA-treated: -41.7 ± 12.3 g; One-Way ANOVA, F = 15.75, p < 0.0001).

DISCUSSION

In summary, we provide functional evidence indicating that NMS strongly affects adult nociception and the efficacy of the oxytocinergic descending inhibitory control. NMS is associated with (i) hypersensitivity to mechanical and thermal hot stimulation at adulthood, (ii) increased vulnerability to **thermal inflammatory-induced hyperalgesia**, and (iii) dysfunction of the OT descending control of pain after non-painful FSS or painful inflammatory sensitization. We further succeeded in rescuing these abnormalities in the nociceptive phenotype by repeated neonatal injections of OT, AP, or SAHA. Altogether, our data suggest that NMS has a strong impact on nociceptive integration, which can blunt the efficacy of descending controls of pain such as the oxytocinergic system which targets the spinal GABAergic inhibitory system. It also suggests that the OT or epigenetic systems can be good targets to develop early treatments to counteract the negative effects of ELS, at least in this model.

Early life events promote nociceptive hypersensitivity and alter OTR-mediated analgesia

Early life stress includes a wide range of adverse events which have long-term negative effects on brain function. In humans, ELS has been associated with an increased risk of developing chronic pain states at adulthood [34], including irritable bowel syndrome [35; 36]. In animal studies, the visceral hypersensitivity following NMS has been widely demonstrated, and correlated with differential activation of supraspinal regions, including the periaqueductal gray, which is a key area for descending pain controls. Here, we confirmed that nociceptive hypersensitivity extends to somatic mechanical and thermal hot stimuli, as previously published by our laboratory [16] and in other ELS models [37-40]. Our observation of an increased thermal pain symptom after carrageenan is consistent with studies showing an increased response after formalin injection [41]

or after partial sciatic ligation [42] in NMS animals. Moreover, OT analgesic action on thermal sensitivity also relies on an action on TRPV1 receptors, since OT seems able to directly activate and promote the rapid desensitization of TRPV1 receptors expressed by C-type sensory fibers [43]. Although not tested in this study, we cannot exclude such an effect in NMS animals, as an increased duration of thermal hot hyperalgesia could be due to the loss of OT action on TRPV1 receptors.

Nociceptive hypersensitivity could be easily explained by a long-lasting up-regulation of voltage-gated channels Nav1.8 and Nav1.9 in DRG neurons as recently published [16].

In this study, impairment of the oxytocinergic pain control has been revealed after recruitment by a non-painful or painful stress. The hypothalamus, where OT producing neurons are located, seems particularly vulnerable to ELS and a dysfunction of the oxytocinergic system may contribute to these alterations as OT plays a key role in the modulation of stress responses, anxiety, social interactions and pain responses. Despite several trials, we have not been able to demonstrate that endogenous OT concentrations are different between groups. Recently, NMS in rodents was shown to be associated with changes in OTR and V1aR binding sites in specific brain regions [44], suggesting a vulnerability of this system to the early environment. In humans, ELS has been associated with low oxytocin concentrations in CSF [45]. Here, we show that OT analgesia is impaired after NMS, both in painful and non-painful conditions. To exert its analgesic effects at the spinal level, OT relays on three main mechanisms: (i) activation of a spinal microcircuit leading to an increased GABAergic inhibitory tone [46], (ii) decrease of the excitability of SC neurons in the superficial layers [47] and (iii) stimulation of allopregnanolone synthesis which further amplifies GABAergic inhibition by allosteric modulation [6]. Here, we showed that spinal OTR are functional in NMS rats and that OTR activation can induce an efficient and transient analgesia, suggesting

that the lack of OT-analgesia could hence result from supraspinal alterations. In agreement with our previously published results [22; 2], we failed to reveal any spinal contribution of the vasopressin V1A receptor in the fine tuning of basal nociceptive threshold or to induce oxytocinergic analgesia after painful or non-painful stress. This control was important since some discrepancies exist in the literature, often pointing out a specie-specific issue and a concentration-dependent action difficult to compare due to different administration procedures ([48]). Exploring hypothalamic OT neurons pharmacological and electrophysiological characteristics might help us to have a deeper understanding of the mechanisms leading to pain-related ELS consequences. A lack of AP synthesis following OTR activation could also explain the lack of OT anti-nociception following carrageenan inflammation in NMS rats, although we found no change in the spinal expression of transcripts coding for proteins responsible for AP synthesis in NMS rats, nor in the spinal expression of OTase mRNA.

Rescuing NMS long-term alterations of the nociceptive system

In our working hypothesis, we asked whether the lack of physical interaction between the mother and the pups could be a critical determinant to explain the deleterious plasticity of the nociceptive system and the deficit in oxytocinergic analgesia. Indeed, mother presence has already been shown to be protective against pain. Kangaroo mother care, in particular, is more frequently recommended and has been shown to have immediate analgesic effect on pain responses in the newborn [49; 50] and to be protective against long term alterations usually following preterm birth [51; 52]. As OT has a key role in the modulation of parental behavior and attachment [53; 54], we performed a rescue experiment by repeated neonatal OT treatment during NMS, which reversed some consequences of NMS on pain behavior. In the literature, OT has been proposed as

1 a therapeutic agent for different neurodevelopmental pathologies such as autism spectrum
2 disorders, since it decreases anxiety and optimizes social behavior [7; 8]. In animal models,
3
4 postnatal injections of OT have been shown to prevent feeding, social and memory deficit in the
5
6 Prader-Willi model [55; 29]. Here, we only studied the beneficial consequences of an early
7
8 treatment with OT on pain behaviors but further experiments would be helpful to confirm if this
9
10 treatment could also counteract the detrimental effects of NMS on pain-related comorbidities
11
12 such as stress and anxiety. These observations might have great clinical relevance in neonatal
13
14 intensive care units since it confirms, once again, the crucial role of physical interactions between
15
16 the parents and the newborn to optimize newborn development and install proper homeostatic
17
18 controls to cope with stress (including pain).
19
20
21
22
23
24
25

26 A close reciprocal relationship exists between the oxytocinergic system and neurosteroids.
27
28 Allopregnanolone is not only a downstream second messenger of OTR activation [6], it has well-
29
30 known anxiolytic, analgesic and neuroprotective properties [31]. In this study, a rescue experiment
31
32 with neonatal allopregnanolone treatment appeared successful to restore normal pain sensitivity
33
34 and a functional OT analgesia after FSS. Neonatal allopregnanolone level alterations can indeed
35
36 lead to changes in behavior at adulthood [56]. Our result is also in good agreement with other
37
38 studies using AP treatment to prevent neonatal anxiety after a short-term NMS (24 hours) [57].
39
40 The mechanisms by which AP could be protective against NMS consequences on pain controls are
41
42 still unknown. However, neonatal AP level alterations could interact with chloride homeostasis
43
44 development, since AP has also been shown to change KCC2 expression in the hippocampus [58].
45
46
47
48
49
50
51

52 Eventually, it is not surprising that HDAC inhibitor and epigenetic changes are involved in the long-
53
54 term consequences of NMS on nociception and OT analgesia. It has long been known that
55
56 neonatal stress has long lasting effects through epigenetic mechanisms [32; 59; 33]. **Epigenetic**
57
58
59
60
61
62
63
64
65

changes in chromatin compaction through histone modification such as histone acetylation have been demonstrated after NMS in different brain areas [59; 60; 19]. Here we also demonstrate that the spinal expression of different pain-related epigenetic factors is altered after NMS, in particular HDAC 1, 7 and 8 which are overexpressed in a long-lasting manner compatible with the observed pain phenotypes. In the pain context, histone acetylation can modulate nociceptive response in inflammatory neuropathic and visceral pain models [61]. Spinal class II HDACs are involved in inflammatory hyperalgesia [62], which could explain the beneficial effects of SAHA treatment observed in this study after carrageenan inflammation, and the critical role of spinal HDAC 7 overexpression in NMS animals. In line, it has been suggested that suppressing HDAC 1 expression in the SC attenuated neuropathic pain symptoms [63]. The OTR gene promoter is also subjected to increased association of acH3K14 after NMS in rats, in critical structures for pain control [64]. However, we did not see any difference in the spinal expression of OTR in our study, providing further evidence that histone modification may be necessary but not sufficient to exert significant and long lasting changes in specific gene expression and that epigenetic alterations targeting the OTR gene may actually be region-dependant.

Corroborating our results, Moloney and colleagues showed that NMS is associated with an alteration in histone acetylation at the spinal level [19] and were the first to show that adult SAHA treatment can reverse NMS-induced visceral hypersensitivity. Here, we show that a preventive neonatal treatment with the same agent is also effective to prevent mechanical and thermal hypersensitivity at adulthood. At this stage, the underlying mechanisms are still to be identified as well as the molecular targets by which SAHA exerts its protective effects against NMS.

In conclusion, NMS induced both a basal hypersensitivity to pain and a dysfunction in OT descending control of pain, in painful and non-painful conditions. Some of these alterations can be

1 rescued by neonatal SAHA or OT/AP treatment, but other alternatives need to be explored to be
2 able to recover completely the OT antinociceptive action under inflammatory conditions. By
3
4 studying the mechanisms of action of these pharmacological treatments, we might be able to
5
6 identify new therapeutic targets to avoid NMS induced reprogramming of pain circuits.
7
8
9

10 11 12 13 14 Acknowledgments 15

16
17 This project has been supported by public funding from University of Strasbourg and CNRS. MM
18
19 and GG are fellows of the French Ministry of research. PEJ was awarded a Gisele Guilbaud/Sfetd
20
21 research price in 2013.
22
23
24

25 Conflict of interest statement 26

27
28 The authors have no conflict of interest.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FIGURES AND LEGENDS

Figure 1. Altered baseline nociceptive sensitivity and stress induced analgesia efficacy in NMS rats. **A.** Baseline nociceptive thresholds for mechanical (left histogram) and thermal hot stimulation (right histogram) between control (black bars) and NMS rats (white bars). Statistical code for: Unpaired Student t-test *** $p < 0.001$ $N = 12/\text{group}$. **B.** Stress induced-analgesia (SIA) detected 20 minutes after a forced swim stress procedure aimed at stimulating OT endogenous controls (10 minutes, water at 20°C) for control ($N = 8$ black bar), NMS ($N = 8$ white bar), control pre-injected with dOVT ($N = 8$ red bar) and NMS rats pre-injected with dOVT ($N = 8$ grey bar). The variation of mechanical threshold in grams has been calculated as: $\Delta = \text{mechanical threshold post FSS} - \text{mechanical threshold pre-FSS}$. Statistical code for One Way ANOVA followed by Tukey post hoc test: *** $p < 0.001$.

Figure 2. Increased sensibility to inflammatory pain in NMS rats. Time course of mechanical (top panels) and thermal hot (bottom panels) nociceptive thresholds for control (A) and NMS rats (B). Carrageenan injection was done at day 0 just after the daily measure. Note that the duration of thermal hyperalgesia was longer for NMS rats. Statistical code for repeated measures Two Way ANOVA treatment X time followed by Sidak post hoc test to compare ipsilateral and contralateral hindpaws for each time point: ** $p < 0.01$, *** $p < 0.001$ $N = 12$ per group.

Figure 3. Lack of efficiency of OT anti-hyperalgesic control on behavioral symptoms of inflammatory pain in NMS rats. Changes in the mean mechanical (A) and thermal hot (B) thresholds, 24 h after a carrageenan hindpaw injection, in control ($N = 10$) and NMS rats ($N = 8$) submitted to a single injection of the selective OTR antagonist dOVT (1 μM , 20 μL) or saline (NaCl 0.9%, 20 μL), measured as: $\Delta = \text{threshold post dOVT injection} - \text{threshold pre dOVT injection}$.

Statistical code for One Way ANOVA and Tukey post hoc test: * $p<0.05$, ** $p<0.01$, *** $p<0.001$.

CTRL: control, NMS: maternal separation, s: saline.

Figure 4. Lack of efficiency of OT anti-nociceptive control on spinal cord wide dynamic range neurons. A and B. Number of action potentials measured during windup when recording from wide dynamic range neurons *in vivo*. Results are given for anesthetized control (CTRL, **A**) and NMS rats (**B**), displaying an hindpaw inflammation for 24 h due to carrageenan injection, and submitted to a repetitive stimulation of the corresponding receptive field on the hindpaw (1Hz, intensity: 3x threshold for C fibers). Windup characteristics are provided before (black symbols) and 20 minutes after local (spinal) application of the selective antagonist dOVT (1 μ M, in red). Statistical code for **repeated measures** Two Way ANOVA Treatment X Time and Sidak post hoc test: * $p<0.05$, *** $p<0.001$. **C.** Mean frequencies of action potential discharge at wind-up plateau phase for all groups. Statistical code for Kruskal Wallis test and Sidak post hoc test: * $p<0.05$ N=6 per group.

Figure 5. Function of OTR in NMS rats. A. Expression of transcripts coding for spinal OTR in control and NMS rats. No significant difference between groups has been detected using Unpaired Student t-test, N=7 control and N=8 NMS. **B.** Changes in mechanical nociceptive threshold in CTRL and NMS rats after i.t injection of OT (1 μ M, 20 μ L, **green triangles**, N=8 for CTRL and N=7 for NMS), TGOT (1 μ M, 20 μ L, **orange squares**, N=8) or vehicle (NaCl, 20 μ L, **white circles**, N=7). Statistical code for **repeated measures** Two-way ANOVA treatment X Time followed by **Tukey's** post hoc test: *** $p<0.001$.

Figure 6. Neonatal treatment with OT or AP can partially suppress NMS consequences. Effect of a neonatal repeated treatment with oxytocin (OT, 1mg/kg o.d. i.p. injections between P2 and P12, purple bars) or allopregnanolone (AP, 10mg/kg i.p. injections between P2 and P12 every 2days, red bars), on mechanical nociceptive thresholds (**A**, N=12 control and N=8 NMS), stress induced

analgesia (SIA) (B, N=9 control and N=8 NMS), and OTR-dependent inhibitory control 24 h after carrageenan inflammation (C, n=8 per group). Results are shown for control (CTRL) and NMS rats. Statistical code for One WAY ANOVA followed by Tukey post hoc test: *p<0.05; **p<0.01; ***p<0.001.

Figure 7. Epigenetic alterations following NMS and partial suppression of NMS consequences after a neonatal treatment with SAHA. **A.** Changes in relative gene expression of spinal transcripts coding for HDAC 1-9 in NMS rats compared to controls, as measured with RT-qPCR, from P7 to P100. A significant increase in the expression of HDAC 1, HDAC 7 and HDAC 8 has been detected at different time points. Statistical code for Kruskal-Wallis followed by Dunn's post hoc test : ++p<0.01; +++p<0.001, with "+" symbolizing and increased in expression in NMS rats compared to controls. **B.** Time course of the expression of transcripts coding for spinal HDAC 7 in control and NMS rats, from P7 to P100. Statistical code for Kruskal-Wallis followed by Dunn's post hoc test : **p<0.01; ***p<0.001. **C to E.** Effect of a neonatal repeated treatment with SAHA (5mg/kg, daily i.p. injection between P2 and P12: dark green), a non-selective HDAC inhibitor, on mechanical nociceptive thresholds (C, N=8 control and NMS, N=10 SAHA treated NMS), stress-induced analgesia (D, N=9 CTRL, N=8 NMS and N=7 SAHA treated NMS), OTR-dependent inhibitory control 24 hours after carrageenan inflammation (E, N=10 ctrl, N=8 NMS N=8 SAHA treated NMS). Results are shown for control (CTRL) and NMS rats. Statistical code for One WAY ANOVA followed by Tukey post hoc test for panels C to E : *p<0.05; *** p<0.001.

Supplementary Figure 1. A. Expression of transcripts coding for spinal OTase in control and NMS rats, as measured by RT-qPCR. No significant difference between conditions has been detected using unpaired Student t-test, N=8 CTRL and NMS. **B.** Expression of transcripts coding for spinal 3 α -HSD, 5 α -reductase II, P450scc and TSPO in control and NMS rats, as measured by RT-

qPCR. No significant difference between conditions has been detected using One Way ANOVA, N=8 CTRL and NMS.

Supplementary Table 1. List of primer sequences used to amplify genes of interest by quantitative RT-PCR.

REFERENCES

- [1]Poisbeau P, Grinevich V, Charlet A. Oxytocin Signaling in Pain: Cellular, Circuit, System, and Behavioral Levels. *Curr Top Behav Neurosci* 2017.
- [2]Eliava M, Melchior M, Knobloch-Bollmann HS, Wahis J, da Silva Gouveia M, Tang Y, Ciobanu AC, Triana Del Rio R, Roth LC, Althammer F, Chavant V, Goumon Y, Gruber T, Petit-Demouliere N, Busnelli M, Chini B, Tan LL, Mitre M, Froemke RC, Chao MV, Giese G, Sprengel R, Kuner R, Poisbeau P, Seeburg PH, Stoop R, Charlet A, Grinevich V. A New Population of Parvocellular Oxytocin Neurons Controlling Magnocellular Neuron Activity and Inflammatory Pain Processing. *Neuron* 2016;89(6):1291-1304.
- [3]Moreno-Lopez Y, Martinez-Lorenzana G, Condes-Lara M, Rojas-Piloni G. Identification of oxytocin receptor in the dorsal horn and nociceptive dorsal root ganglion neurons. *Neuropeptides* 2013;47(2):117-123.
- [4]Martinez-Lorenzana G, Espinosa-Lopez L, Carranza M, Aramburo C, Paz-Tres C, Rojas-Piloni G, Condes-Lara M. PVN electrical stimulation prolongs withdrawal latencies and releases oxytocin in cerebrospinal fluid, plasma, and spinal cord tissue in intact and neuropathic rats. *Pain* 2008;140(2):265-273.
- [5]Wotjak CT, Ganster J, Kohl G, Holsboer F, Landgraf R, Engelmann M. Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. *Neuroscience* 1998;85(4):1209-1222.
- [6]Juif PE, Breton JD, Rajalu M, Charlet A, Goumon Y, Poisbeau P. Long-lasting spinal oxytocin analgesia is ensured by the stimulation of allopregnanolone synthesis which potentiates GABA(A) receptor-mediated synaptic inhibition. *J Neurosci* 2013;33(42):16617-16626.
- [7]Modi ME, Young LJ. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. *Horm Behav* 2012;61(3):340-350.
- [8]Young LJ, Barrett CE. Neuroscience. Can oxytocin treat autism? *Science* 2015;347(6224):825-826.
- [9]Simons SH, Tibboel D. Pain perception development and maturation. *Semin Fetal Neonatal Med* 2006;11(4):227-231.
- [10]Schwaller F, Fitzgerald M. The consequences of pain in early life: injury-induced plasticity in developing pain pathways. *Eur J Neurosci* 2014;39(3):344-352.
- [11]Fitzgerald M. The development of nociceptive circuits. *Nat Rev Neurosci* 2005;6(7):507-520.
- [12]Hartley C, Moultrie F, Gursul D, Hoskin A, Adams E, Rogers R, Slater R. Changing Balance of Spinal Cord Excitability and Nociceptive Brain Activity in Early Human Development. *Curr Biol* 2016;26(15):1998-2002.

- [13]Beggs S, Torsney C, Drew LJ, Fitzgerald M. The postnatal reorganization of primary afferent input and dorsal horn cell receptive fields in the rat spinal cord is an activity-dependent process. *Eur J Neurosci* 2002;16(7):1249-1258.
- [14]Ben-Ari Y. The GABA excitatory/inhibitory developmental sequence: a personal journey. *Neuroscience* 2014;279:187-219.
- [15]O'Mahony SM, Hyland NP, Dinan TG, Cryan JF. Maternal separation as a model of brain-gut axis dysfunction. *Psychopharmacology (Berl)* 2011;214(1):71-88.
- [16]Juif PE, Salio C, Zell V, Melchior M, Lacaud A, Petit-Demouliere N, Ferrini F, Darbon P, Hanesch U, Anton F, Merighi A, Lelievre V, Poisbeau P. Peripheral and central alterations affecting spinal nociceptive processing and pain at adulthood in rats exposed to neonatal maternal deprivation. *Eur J Neurosci* 2016;44(3):1952-1962.
- [17]Sengupta JN. Visceral pain: the neurophysiological mechanism. *Handb Exp Pharmacol* 2009(194):31-74.
- [18]Theodorou V. Susceptibility to stress-induced visceral sensitivity: a bad legacy for next generations. *Neurogastroenterol Motil* 2013;25(12):927-930.
- [19]Moloney RD, Stilling RM, Dinan TG, Cryan JF. Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition. *Neurogastroenterol Motil* 2015;27(12):1831-1836.
- [20]Luis-Delgado OE, Barrot M, Rodeau JL, Schott G, Benbouzid M, Poisbeau P, Freund-Mercier MJ, Lasbennes F. Calibrated forceps: a sensitive and reliable tool for pain and analgesia studies. *J Pain* 2006;7(1):32-39.
- [21]Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* 1988;32(1):77-88.
- [22]Juif PE, Poisbeau P. Neurohormonal effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats. *Pain* 2013;154(8):1449-1456.
- [23]Mendell LM. Physiological properties of unmyelinated fiber projection to the spinal cord. *Exp Neurol* 1966;16(3):316-332.
- [24]Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987;162(1):156-159.
- [25]Lelievre V, Hu Z, Byun JY, Ioffe Y, Waschek JA. Fibroblast growth factor-2 converts PACAP growth action on embryonic hindbrain precursors from stimulation to inhibition. *J Neurosci Res* 2002;67(5):566-573.
- [26]Robinson DA, Wei F, Wang GD, Li P, Kim SJ, Vogt SK, Muglia LJ, Zhuo M. Oxytocin mediates stress-induced analgesia in adult mice. *J Physiol* 2002;540(Pt 2):593-606.
- [27]Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? *Prog Neurobiol* 2000;61(2):169-203.

- [28]Bakos J, Lestanova Z, Strbak V, Havranek T, Bacova Z. Neonatal manipulation of oxytocin prevents lipopolysaccharide-induced decrease in gene expression of growth factors in two developmental stages of the female rat. *Neuropeptides* 2014;48(5):281-286.
- [29]Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F, Guillon G, Lafitte D, Desarmenien MG, Tauber M, Muscatelli F. An Early Postnatal Oxytocin Treatment Prevents Social and Learning Deficits in Adult Mice Deficient for *Magel2*, a Gene Involved in Prader-Willi Syndrome and Autism. *Biol Psychiatry* 2015;78(2):85-94.
- [30]Lovic V, Gonzalez A, Fleming AS. Maternally separated rats show deficits in maternal care in adulthood. *Dev Psychobiol* 2001;39(1):19-33.
- [31]Poisbeau P, Keller AF, Aouad M, Kamoun N, Groyer G, Schumacher M. Analgesic strategies aimed at stimulating the endogenous production of allopregnanolone. *Front Cell Neurosci* 2014;8:174.
- [32]Champagne FA. Epigenetic mechanisms and the transgenerational effects of maternal care. *Front Neuroendocrinol* 2008;29(3):386-397.
- [33]Buschdorf JP, Meaney MJ. Epigenetics/Programming in the HPA Axis. *Compr Physiol* 2015;6(1):87-110.
- [34]Davis DA, Luecken LJ, Zautra AJ. Are reports of childhood abuse related to the experience of chronic pain in adulthood? A meta-analytic review of the literature. *Clin J Pain* 2005;21(5):398-405.
- [35]Salmon P, Skaife K, Rhodes J. Abuse, dissociation, and somatization in irritable bowel syndrome: towards an explanatory model. *J Behav Med* 2003;26(1):1-18.
- [36]Ross CA. Childhood sexual abuse and psychosomatic symptoms in irritable bowel syndrome. *J Child Sex Abus* 2005;14(1):27-38.
- [37]Takatsuru Y, Yoshitomo M, Nemoto T, Eto K, Nabekura J. Maternal separation decreases the stability of mushroom spines in adult mice somatosensory cortex. *Brain Res* 2009;1294:45-51.
- [38]Pierce AN, Ryals JM, Wang R, Christianson JA. Vaginal hypersensitivity and hypothalamic-pituitary-adrenal axis dysfunction as a result of neonatal maternal separation in female mice. *Neuroscience* 2014;263:216-230.
- [39]Yasuda M, Shinoda M, Honda K, Fujita M, Kawata A, Nagashima H, Watanabe M, Shoji N, Takahashi O, Kimoto S, Iwata K. Maternal Separation Induces Orofacial Mechanical Allodynia in Adulthood. *J Dent Res* 2016;95(10):1191-1197.
- [40]Amini-Khoei H, Amiri S, Mohammadi-Asl A, Alijanpour S, Poursaman S, Haj-Mirzaian A, Rastegar M, Mesdaghinia A, Banafshe HR, Sadeghi E, Samiei E, Mehr SE, Dehpour AR. Experiencing neonatal maternal separation increased pain sensitivity in adult male mice: Involvement of oxytocinergic system. *Neuropeptides* 2017;61:77-85.

- [41]Uhelski ML, Fuchs PN. Maternal separation stress leads to enhanced emotional responses to noxious stimuli in adult rats. *Behav Brain Res* 2010;212(2):208-212.
- [42]Nishinaka T, Kinoshita M, Nakamoto K, Tokuyama S. Sex differences in depression-like behavior after nerve injury are associated with differential changes in brain-derived neurotrophic factor levels in mice subjected to early life stress. *Neurosci Lett* 2015;592:32-36.
- [43]Nersesyan Y, Demirkhanyan L, Cabezas-Bratesco D, Oakes V, Kusuda R, Dawson T, Sun X, Cao C, Cohen AM, Chelluboina B, Veeravalli KK, Zimmermann K, Domene C, Brauchi S, Zakharian E. Oxytocin Modulates Nociception as an Agonist of Pain-Sensing TRPV1. *Cell Rep* 2017;21(6):1681-1691.
- [44]Lukas M, Bredewold R, Neumann ID, Veenema AH. Maternal separation interferes with developmental changes in brain vasopressin and oxytocin receptor binding in male rats. *Neuropharmacology* 2010;58(1):78-87.
- [45]Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. Lower CSF oxytocin concentrations in women with a history of childhood abuse. *Mol Psychiatry* 2009;14(10):954-958.
- [46]Breton JD, Veinante P, Uhl-Bronner S, Vergnano AM, Freund-Mercier MJ, Schlichter R, Poisbeau P. Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition. *Mol Pain* 2008;4:19.
- [47]Breton JD, Poisbeau P, Darbon P. Antinociceptive action of oxytocin involves inhibition of potassium channel currents in lamina II neurons of the rat spinal cord. *Mol Pain* 2009;5:63.
- [48]Schorscher-Petcu A, Sotocinal S, Ciura S, Dupre A, Ritchie J, Sorge RE, Crawley JN, Hu SB, Nishimori K, Young LJ, Tribollet E, Quirion R, Mogil JS. Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. *J Neurosci* 2010;30(24):8274-8284.
- [49]Johnston CC, Stevens B, Pinelli J, Gibbins S, Filion F, Jack A, Steele S, Boyer K, Veilleux A. Kangaroo care is effective in diminishing pain response in preterm neonates. *Arch Pediatr Adolesc Med* 2003;157(11):1084-1088.
- [50]Ludington-Hoe SM, Hosseini R, Torowicz DL. Skin-to-skin contact (Kangaroo Care) analgesia for preterm infant heel stick. *AACN Clin Issues* 2005;16(3):373-387.
- [51]Feldman R, Rosenthal Z, Eidelman AI. Maternal-preterm skin-to-skin contact enhances child physiologic organization and cognitive control across the first 10 years of life. *Biol Psychiatry* 2014;75(1):56-64.
- [52]Charpak N, Tessier R, Ruiz JG, Hernandez JT, Uriza F, Villegas J, Nadeau L, Mercier C, Maheu F, Marin J, Cortes D, Gallego JM, Maldonado D. Twenty-year Follow-up of Kangaroo Mother Care Versus Traditional Care. *Pediatrics* 2017;139(1).

- [53]Carter CS. Oxytocin pathways and the evolution of human behavior. *Annu Rev Psychol* 2014;65:17-39.
- [54]Feldman R. The Neurobiology of Human Attachments. *Trends Cogn Sci* 2017;21(2):80-99.
- [55]Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F. A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted *Magel2* gene. *Hum Mol Genet* 2010;19(24):4895-4905.
- [56]Darbra S, Modol L, Llido A, Casas C, Vallee M, Pallares M. Neonatal allopregnanolone levels alteration: effects on behavior and role of the hippocampus. *Prog Neurobiol* 2014;113:95-105.
- [57]Llido A, Modol L, Darbra S, Pallares M. Interaction between neonatal allopregnanolone administration and early maternal separation: effects on adolescent and adult behaviors in male rat. *Horm Behav* 2013;63(4):577-585.
- [58]Modol L, Casas C, Llido A, Navarro X, Pallares M, Darbra S. Neonatal allopregnanolone or finasteride administration modifies hippocampal K(+) Cl(-) co-transporter expression during early development in male rats. *J Steroid Biochem Mol Biol* 2014;143:343-347.
- [59]Murgatroyd C, Spengler D. Epigenetic programming of the HPA axis: early life decides. *Stress* 2011;14(6):581-589.
- [60]Levine A, Worrell TR, Zimnisky R, Schmauss C. Early life stress triggers sustained changes in histone deacetylase expression and histone H4 modifications that alter responsiveness to adolescent antidepressant treatment. *Neurobiol Dis* 2012;45(1):488-498.
- [61]Wang W, Cui SS, Lu R, Zhang H. Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain? *Brain Res Bull* 2016;125:44-52.
- [62]Bai G, Wei D, Zou S, Ren K, Dubner R. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. *Mol Pain* 2010;6:51.
- [63]Cherng CH, Lee KC, Chien CC, Chou KY, Cheng YC, Hsin ST, Lee SO, Shen CH, Tsai RY, Wong CS. Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats. *J Formos Med Assoc* 2014;113(8):513-520.
- [64]Litvin Y, Turner CA, Rios MB, Maras PM, Chaudhury S, Baker MR, Blandino P, Jr., Watson SJ, Jr., Akil H, McEwen B. Fibroblast growth factor 2 alters the oxytocin receptor in a developmental model of anxiety-like behavior in male rat pups. *Horm Behav* 2016;86:64-70.

Maternal separation renders adult rats hypersensitive to noxious stimuli and incapable to recruit oxytocin analgesic controls. Rescue is achieved by neonatal treatments with oxytocin, allopregnanolone or HDAC inhibitors.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

A1. **B1.** **A2.** **B2.**

Name	Reference sequence	Amplicon region	Forward sequence (5' to 3')	Reverse sequence (5' to 3')
3α-HSD	NM138547	330 - 423	ACCAGAGCTGGTCCGAACCTT	CAAAGCCATTGGGAAATGAA
5α-red II	NM022711	49 - 146	TGCAGATTGTCTGCCATCAG	GTAAGTGGCGGGTTTCCCTA
HDAC 1	NM001025409	247 - 344	CGTTCTATTGCCCCAGATAAC	AACTCAAACAAGCCATCAAAT
HDAC 2	NM053447	1415 - 1510	AATTTCCATTGAGCATCAGA	TCAGCAACATTCCTACGACCT
HDAC 3	NM053448	1238 - 1346	GGGGTCCTGAGGAGAACTAC	CATCCATGCTGCTCTTAAATC
HDAC 4	NM053449	986 - 1089	ATGTACGACGCCAAAGATGA	CTGCTCCGTCTCTCAGCTACT
HDAC 5	NM053450	2084 - 2184	GAGGAGGACTGCATTGAGGTC	GCGAACAACCTTTTGTAAACCA
HDAC 6	KY009929	1929 - 2015	AATCGTGGATTGGGATGTTC	CGGTGCAGGGACACGTATAAT
HDAC 7	AF321135	472 - 564	CCCCTGCGTAAACAGTGTCT	CTTCCTGAGCAGGGGATT
HDAC 8	NM001126373	921 - 1023	GACTGTGTCCCTGCACAAGTT	GGGCACATTGACACTGTAGT
HDAC 9	NM001200045	1666 - 1775	CCTGGAGAAGCAGAAGCAATA	CCTCCTCTGCCTCTTCAAGAT
HPRT	NM012583	558 - 647	GGTGAAAAGGACCTCTCGAA	TCAAGGGCATATCCAACAACA
OT	NM012996	80 - 164	CTCTGACCTCCGCCTGCTA	GGAAGACACTTGCGCATATCC
OTR	NM012871	732 - 825	TCGCCGTCTACATTGTACCG	GCTGCCGTCTTGAGTCTCAG
OTase	NM001113403	1934 - 2029	CCAGAGAAAGGGGACTGAGC	TGCCAAAGGTGGCTTGTATC
P450_{scc}	NM017286	679 - 780	GATGTTGGAGGAGATCGTGGA	AAGTCTGGAGGCATGTTGAGC
TSPO	NM012515	152 - 243	ATGGGAGCCTACTTTGTGCGT	GGAGCGAGTGTCCAGCGA